CyberKnife Dose Escalation Prostate Cancer Trial (CK-DESPOT)
CyberKnife Dose Escalation for Unfavorable and High-risk Prostate Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
The optimal radiation schedule for the curative treatment of prostate cancer remains unknown. Prostate cancer patients receiving radiation therapy are typically treated 5 days per week for 8-9 weeks. Recent data suggest that large radiation fraction sizes are radio-biologically favorable over lower fraction sizes in prostate cancer radiotherapy. The sensitivity of a tumor or normal tissue to fraction size of radiation can be approximated by the alpha-beta ratio. It has been suggested that the alpha/beta ratio for prostate cancer is actually as low as 1.5 implying that the current radiation therapy paradigm for prostate cancer treatment might be fundamentally flawed, as high fraction sizes would be expected to damage tumor more readily.
Typical prostate SBRT doses do not appear to have similar efficacy in higher risk prostate cancer suggesting even higher doses are required. Many techniques including dose escalated external beam radiation therapy (EBRT), proton therapy (PT) and brachytherapy have been employed to increase dose to the prostate. Data from the ASCEND-RT trial utilizing low dose rate brachytherapy boost showed a dramatic 21% improvement in biochemical control at 9 years favoring brachytherapy boost compared to conventional dose escalated EBRT radiation therapy. However, no corresponding benefit was identified in overall survival, incidence of bone metastases or prostate cancer specific mortality while a 3 fold increase in late urinary toxicity was noted.
SBRT is well tolerated with minimal acute and late side effects. In this protocol, CK-SBRT will be used to target the microscopic and gross disease in the prostate, seminal vesicles. An escalated dose of 40 Gy in 5 fractions will be delivered to the entire target volume while any nodules visible within the prostate gland on endorectal MRI will receive 50 Gy in 5 fractions.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19083
- Philadelphia CyberKnife
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the prostate diagnosed within 360 days of enrollment.
- Prostate Specific Antigen (PSA) documented within 90 days prior to registration.
- Clinical staging completed within 90 days of registration.
- No Nodal or Distant Metastases documented on CT or MRI of the pelvis and bone scan.
- Unfavorable Risk Prostate Carcinoma as Described is documented.
- No prior pelvic radiotherapy.
- No prior Trans-urethral resection of the prostate (TURP).
- Prostate volume < 100 cc
- American Urologic Association (AUA) score < 20
- No recent (within 5 years) or concurrent cancers other than non-melanoma skin cancers.
- Patient must have no medical or psychiatric illnesses that would interfere with treatment or follow-up.
- No implanted hardware adjacent to the prostate that would prohibit appropriate treatment planning and treatment delivery is allowed.
- Candidate for rectal spacer placement
Exclusion Criteria:
- Other cancer diagnosis other than non-melanoma skin cancer with 5 years
- Prostate size greater than 100cc
- AUA greater than 20
- Implanted hardware impacting imaging
- Metastatic prostate cancer
- Contraindication to hormone therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Dose Escalated CyberKnife SBRT
DE-SBRT will be delivered using the CyberKnife robotic radiosurgery system.
Patients will be treated with five SBRT treatments (8 Gy per fraction to the PTV, and 9-10 Gy per fraction to any nodules identified on endorectal MRI) over 7-10 days.
|
Radiation Therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bladder and Rectal Toxicity using NCI common toxicity criteria version 4.0
Time Frame: 24 Months
|
Genitourinary or Bowel Toxicity as a result of radiation therapy will be reported using
|
24 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Biochemical Disease Free Survival
Time Frame: 24 Months
|
Time in months from completion of SBRT to biochemical failure
|
24 Months
|
|
Duration of local control
Time Frame: 24 Months
|
time in months from SBRT completion to local failure
|
24 Months
|
|
Distant Failure
Time Frame: 24 Months
|
time in months from SBRT completion to distant failure
|
24 Months
|
|
Disease Free Survival
Time Frame: 24 Months
|
time in months from the date that the patient is determined to be free of disease to the date of known disease recurrence for any measure of disease.
|
24 Months
|
|
Disease Specific Survival
Time Frame: 24 Months
|
time in months from completion of SBRT to death due to prostate cancer, other causes with active malignancy, or complications from treatment.
|
24 Months
|
|
Overall Survival
Time Frame: 5 years
|
ime in months from SBRT completion until death
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Rachelle Lanciano, MD, Philadelphia CyberKnife -Crozer Health
- Principal Investigator: Rachelle Lanciano, MD, Philadelphia CyberKnife -Crozer Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCK-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.